As health and longevity have become trending topics, NAD+ (Nicotinamide Adenine Dinucleotide) and its related compounds have long been "star molecules" in the field of anti-aging. Recent regulatory updates on NMN have also attracted widespread attention.
This article provides an in-depth analysis of the core differences between key members of the NAD+ family, the latest global regulatory developments, and the evolution of NAD+ products, to deliver a comprehensive science-backed guide to NAD+ anti-aging.
Core Differences Between Key Members of the NAD+ Family
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ is a critical coenzyme and signaling molecule in the human body, with core functions spanning energy metabolism, DNA damage repair (dependent on PARP enzymes), gene expression regulation (dependent on sirtuin deacetylases), and cellular senescence regulation. It serves as the "energy hub" and "repair switch" that maintains normal cellular function and vital life activities.
Biosynthesis Pathways of NAD+
NAD+ in the human body is synthesized mainly through two pathways:
- De Novo Biosynthesis Pathway: Starting with tryptophan as the raw material, it is gradually converted through the kynurenine pathway to produce nicotinic acid mononucleotide (NaMN), which is then further synthesized into NAD+. This pathway is active in organs such as the liver, but has low efficiency and is heavily influenced by tryptophan intake and metabolic status.
- Salvage Pathway: Uses precursors such as nicotinamide (NAM), nicotinamide riboside (NR), and β-nicotinamide mononucleotide (NMN) as raw materials.
In this pathway, NAM is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT, the key rate-limiting enzyme in the salvage pathway) to produce NMN, which is then catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT) to generate NAD+.
NR and NMN can directly enter the downstream steps of this pathway, bypassing the NAMPT rate-limiting step, making them the primary pathways for exogenous NAD+ supplementation.
Absorption and Utilization Characteristics
Endogenous NAD+ is mainly generated through the conversion of precursors (such as NMN and NR). Its levels gradually decline with age (due to decreased NAMPT activity and increased consumption by the CD38 enzyme), unhealthy lifestyle habits (staying up late, excessive alcohol consumption), and disease states.
NAD+ has a large molecular weight and is charged, making it difficult to cross the intestinal barrier after oral administration. It is easily broken down by digestive enzymes into small fragments such as nicotinamide, resulting in extremely low oral bioavailability.
NADH (Reduced Form of NAD+)
NADH is the reduced form of NAD+. Its core function is to act as an electron carrier in energy metabolism, accepting hydrogen atoms and electrons in glycolysis and the tricarboxylic acid (TCA) cycle. It then transfers electrons through the mitochondrial respiratory chain to release energy, while being converted back to NAD+.
Conversion Pathway of NADH
NADH is a direct energy-carrying NAD+ precursor. Unlike other precursors (such as NMN and NR) that require ATP consumption for multi-step conversion to generate NAD+, NADH itself contributes to ATP synthesis through the electron transport chain during its conversion to NAD+, with a theoretically shorter and more efficient conversion pathway.
- Endogenous conversion: During energy metabolism, NAD+ accepts electrons and hydrogen atoms and is reduced to NADH, which is then oxidatively dehydrogenated via the respiratory chain to regenerate NAD+, forming the "NAD+-NADH cycle" to sustain continuous energy metabolism.
- Exogenous supplementation: After oral administration, NADH must first be dehydrogenated and converted to NAD+ intracellularly before participating in NAD+-dependent physiological processes, essentially acting indirectly through conversion to NAD+.
Absorption and Utilization Characteristics
NADH has poor stability and is easily degraded by gastric acid and digestive enzymes (such as nucleases), resulting in low oral bioavailability.
Current technologies such as microencapsulation and liposomal delivery can improve the stability and absorption efficiency of NADH in the intestinal tract. However, more research is needed to support whether it can effectively penetrate cell membranes (including brain cells) after entering the bloodstream. In addition, the efficiency of NADH conversion to NAD+ is affected by cellular energy demand and NADH dehydrogenase activity.
Related Research
Clinical studies have shown that NADH supplementation can improve fatigue scores in patients with chronic fatigue syndrome, and has a certain auxiliary effect on improving motor function in patients with Parkinson's disease.
NR (Nicotinamide Riboside)
NR is the direct precursor of NMN, a derivative of vitamin B3. Its core advantages are a short conversion pathway and low toxicity. It can bypass the rate-limiting enzyme (NAMPT) of the NAD+ salvage pathway, and is directly catalyzed by nicotinamide riboside kinases (NRK1/2) in cells to generate NMN, which is then rapidly converted to NAD+. It is one of the most widely used NAD+ precursors in clinical research today.
Absorption and Utilization Characteristics
NR has a small molecular weight and is neutral, allowing it to rapidly cross the intestinal barrier after oral administration.
After entering the bloodstream, it is mainly taken up by organs such as the liver, kidneys, and brain, and is efficiently converted to NMN in cells via NRK (the activity of this enzyme is not significantly inhibited by age or disease), making this conversion pathway relatively efficient. In addition, NR supplementation has been shown to increase NAD+ levels in the central nervous system.
Related Research
Multiple trials have shown that oral administration of 100-1000mg of NR daily in healthy adults significantly increases blood NAD+ levels, with no significant adverse events observed with short-term supplementation.
A phase II randomized, double-blind, placebo-controlled clinical trial showed that daily NR supplementation in patients with Parkinson's disease, over a sustained period, not only significantly increased total NAD levels in the brain, but also improved cerebral energy metabolism, reduced inflammatory markers, and showed a trend toward improved motor function.
Studies have shown that NR has a positive effect on patients with chronic obstructive pulmonary disease (COPD). After 6 weeks of supplementation, patients had increased blood NAD+ levels and reduced inflammatory factors.
A double-blind, placebo-controlled clinical study on Werner syndrome, published in Aging Cell in June 2025, attracted widespread attention. Werner syndrome is caused by mutations that impair DNA repair, leading to cellular senescence decades ahead of the normal progression. The study found that daily NR supplementation significantly increased blood NAD+ levels in patients with Werner syndrome by approximately 140%, improved arterial stiffness (a marker of cardiovascular disease risk), reduced the area of skin ulcers, and appeared to slow the progression of renal dysfunction.
NMN (β-Nicotinamide Mononucleotide)
NMN is a key direct precursor for NAD+ synthesis. Its core advantage is that it requires only one step of reaction (catalyzed by NMNAT) to be converted into NAD+, resulting in high conversion efficiency. It is also a naturally occurring substance in the human body with excellent biocompatibility, making it one of the most intensively researched precursors in the field of NAD+ supplementation.
Biosynthesis Pathways of NMN
- Endogenous synthesis: Endogenous NMN is mainly produced through two pathways: one is the generation from nicotinamide (NAM) catalyzed by the rate-limiting enzyme NAMPT; the other is the generation from NR catalyzed by NRK kinases. The decline in NAMPT activity with age is one of the key factors leading to the depletion of endogenous NAD+ levels.
- Exogenous supplementation and new insights into absorption: A study published in Science Advances in 2025 revealed that the vast majority (approximately 90%) of orally administered NMN is not directly absorbed, but enters the colon where it is metabolized by the gut microbiota into small molecules such as nicotinic acid (NA).
These metabolites are then efficiently synthesized into NAD+ in the liver via the Preiss-Handler pathway through enterohepatic circulation, and then distributed throughout the body. Germ-free mouse experiments found that the integrity of the gut microbiota may be a necessary condition for NMN to increase systemic NAD+ levels, indicating that individual differences in gut health may be a key variable affecting the efficacy of NMN supplementation.
Related Research
A team led by Professor Qu Lefeng from the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) completed China's first human clinical trial of NMN for anti-aging conducted in a tertiary hospital, marking a new stage of evidence-based clinical research in this field.
The results showed that compared with the placebo group, subjects taking NMN had significantly elevated levels of aging-related metabolites downstream of NMN in the blood. More importantly, when measured using NAD-capped RNA as a "biological age clock", the biological age of the NMN group was significantly reduced.
In addition to objective indicators, the study also recorded improvements in the subjects' subjective feelings: for example, 70% of subjects reported reduced daily fatigue, 60% had lower daily blood pressure readings, and 55% felt improved motor function, reflecting the potential value of NMN in improving overall quality of life.
New Global Regulatory Landscape: Latest Compliance Updates for NAD+ Family Members
-
NAD+There is currently no formal regulatory framework for NAD+ worldwide, and it remains in a regulatory gray area. Major regulatory bodies such as the U.S. FDA, EU EFSA, and Japan MHLW have not approved it as a dietary supplement or food ingredient. Most NAD+ products on the market today operate on the edge of non-compliance, with no clear legal status, requiring caution when purchasing.
-
NADHThe regulatory status of NADH is largely consistent with that of NAD+: there is a lack of globally unified regulatory standards, and it has not received official approval from major regional regulatory bodies. No special regulatory policies for NADH have been updated in any region to date, and it remains in an "unclassified" status. The market access of NADH products mainly depends on the leniency of local regulation, with relatively high compliance risks.
-
NRNR is the most fully safety-certified precursor in the NAD+ family, with a clear legal status in most regions except China.
- Europe and the US: The EU EFSA and U.S. FDA have recognized NR as an eligible raw material for dietary supplements, allowing legal production and sales by enterprises.
- China: NR has not yet been approved as a raw material for food or health food.
- Other regions: Canada, for example, has included NR in its Natural Health Product (NHP) notification system, where enterprises can sell products normally once they complete the notification in accordance with standards.
-
NMN (Key Regulatory Turning Point in 2025)NMN is the ingredient with the greatest regulatory disparities. In 2025, policies in many countries and regions have undergone key adjustments, shifting from a previous "ban or ambiguous status" to "gradual clarification", detailed as follows:
-
United States: From "Ban" to "Restored Legality"
In 2022, the U.S. FDA banned NMN from being sold as a dietary supplement under the "drug exclusion clause", deeming it a potential drug. However, in September 2025, the FDA officially revoked this "new drug designation" and restored the legal status of NMN as a dietary supplement.The core reason is that the Natural Products Association (NPA) provided evidence that NMN was already sold as a dietary supplement in 2017, prior to the relevant new drug research, complying with the "pre-drug marketing" principle for dietary supplements. Major U.S. e-commerce platforms have gradually resumed the listing of NMN products.
-
European Union: Launched "Novel Food" Safety Assessment
In July 2025, the EU EFSA officially launched the safety assessment of NMN as a "Novel Food". Chinese enterprises have already submitted applications and entered the risk assessment phase. According to the EU process, the assessment results are expected to be released in 2026.
-
Japan: Maintained "Ordinary Food Ingredient" Status
Japan's Ministry of Health, Labour and Welfare (MHLW) clarified the "ordinary food ingredient" status of NMN as early as 2020, with no new restrictions added in 2025. Enterprises can normally carry out production and sales, and the Japanese market has a rich range of NMN products.
-
China: Accepted as a "Food Additive"
In January 2025, China's National Health Commission included NMN in the acceptance list of "new varieties of food additives", but the results have not yet been announced.
-
United States: From "Ban" to "Restored Legality"
Three Major Evolution Directions of NAD+ Products: From "Single Supplementation" to "Precision Anti-Aging"
As the understanding of NAD+ family ingredients deepens, related products are constantly evolving, from the early competition of single purity to increasingly precise and efficient solutions, with three major directions worthy of attention:
1. Dosage: Balancing Efficacy and Safety
Currently, the single-serving content of global NMN products ranges from 250mg to 1000mg, with high-dose products (e.g., over 500mg per serving) dominating the market due to higher consumer demand for potency.
However, it should be noted that there is no unified "optimal dosage standard" to date, and dosage setting needs to balance theoretical effectiveness and safety. While some studies have shown that high doses may increase blood NAD+ levels, there is a lack of large-sample human clinical data to support a direct correlation between dosage and efficacy. Therefore, the long-term safety of high-dose products requires further verification, and consumers do not need to blindly pursue higher dosages, but should choose according to their own conditions.
2. Complex Formulas: From Single Ingredient to Synergistic Effects
Early NAD+-related products mostly took 99% high purity as their core selling point, but such single-ingredient products are gradually exiting the market, with "NMN+" complex formulas becoming the mainstream. There is also a growing adoption of strategies that combine NAD+ precursors (such as NMN and NR) with AMPK activators.
The core logic of this design is to achieve synergistic effects through multi-target action, and address the limitations that may exist with long-term single supplementation of NAD+ precursors.
How does AMPK activation increase NAD+ levels?
- Promote synthesis: Activated AMPK can directly upregulate the gene expression and activity of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. Enhanced NAMPT activity significantly accelerates the synthesis rate from raw material NAM to NMN, thereby effectively increasing NAD+ levels.
- Reduce consumption: AMPK activation has been shown to inhibit the activity of CD38, the main NAD+-consuming enzyme. CD38 becomes overactivated with age, consuming large amounts of NAD+, and is a major cause of age-related NAD+ decline. Inhibiting CD38 is equivalent to "reducing expenditure" for NAD+, jointly helping to maintain its levels.
Additional benefits of AMPK activation include the regulation of bioenergy metabolism (improving hyperglycemia, hypercholesterolemia, and hyperlipidemia), as well as antidepressant and neuroprotective effects (promoting mitochondrial autophagy and synthesis, reducing amyloid in the brain, and increasing brain-derived neurotrophic factor <BDNF>).
3. Delivery Technologies: Breaking Through Absorption Bottlenecks
No matter how good the ingredients are or how comprehensive the formula is, the effect will be greatly compromised if they cannot be absorbed.
To solve the absorption challenge, pharmaceutical-grade delivery technologies are being widely applied, mainly in the following directions:
-
Liposomal Encapsulation TechnologyThis technology wraps active ingredients (such as NMN or NADH) in "lipid vesicles" with a structure similar to the cell membrane. This protective film can effectively protect the active ingredients from degradation during transportation and in the digestive tract, while using the properties of liposomes to improve the efficiency of crossing intestinal epithelial cells, thereby helping more active ingredients enter the blood circulation. For unstable NADH, liposomal encapsulation also prevents its oxidative degradation.
-
Small Intestine Targeted Delivery and Enteric Coating TechnologyThis technology is designed to allow active ingredients to avoid the gastric acid environment and accurately reach the small intestine, which has stronger absorption capacity. For example, enteric coating puts a "protective layer" on the supplement, allowing it to safely pass through the stomach and only dissolve and release in the neutral or weakly alkaline environment of the intestine. In addition, some technologies use specific transporters in the intestine (such as SLC12A8) to design targeted preparations, allowing NMN to be accurately released in the small intestine and bind to transporters to enter cells, reducing loss.
-
Other Stabilization and Absorption-Enhancing Technologies
- Special processes for NADH: In addition to liposomes, some products use multi-layer coating, acid control technology (to ensure NADH passes through the stomach smoothly) and FDS delivery technology (to accurately deliver NADH to the small intestine) to ensure its stability and bioavailability.
- Sublingual instant dissolution: Absorbed through the sublingual mucosa, allowing active ingredients to directly enter the blood circulation, bypassing the hepatic "first-pass metabolism", thereby improving utilization efficiency.
The core goal of these delivery technologies is to solve the pain point of "supplementation ≠ absorption" — the effectiveness of raw materials also relies on delivery technologies to be realized.
The above content is intended to provide general popular science knowledge related to medical, health, and medication, and is for reference only. It cannot replace any personal medical diagnosis and treatment advice. If you have any health problems, please consult a professional doctor in a timely manner.
References
[1] Chen Z, Wang H, Wang Q. Therapeutic potential of NADH: neurodegenerative diseases characterized by mitochondrial dysfunction [J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2024, 38 (1): 57-62. DOI: 10.13201/j.issn.2096-7993.2024.01.009.
[2] Berven H, Kverneng S, Sheard E, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease[J]. Nature Communications, 2023, 14: 7793.
[3] Norheim KL, Ben Ezra M, Heckenbach I, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial[J]. Nature Aging, 2024, 4: 1772-1781.
[4] Shoji M, Kato H, Koshizaka M, et al. Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial. Aging Cell. 2025 Aug;24(8):e70093. doi: 10.1111/acel.70093.
[5] Yaku K, Palikhe S, Iqbal T, et al. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD⁺ synthesis via enterohepatic circulation[J]. Science Advances, 2025, 11(12): eadr1538.